Since the 2013 Regenerative Medicine Laws took effect, Japan has poured resources into advancing regenerative therapies. Yet, no Japanese product has successfully launched overseas, sparking national debate over the industry's progress.
 
At BIOJAPAN 2023, four experts offered key recommendations for a much-needed "growth spurt":
1. Establish a "re-evaluation" system for regenerative products to enhance market readiness.
2. Leverage four collaborative models to strengthen global interactions.
3. Improve global awareness of Japan’s unique advantages in regenerative medicine.
4. Encourage startups to focus on M&A as an exit strategy, aligning with international practices.
 
Can Japan overcome these challenges to regain its momentum in the global regenerative medicine race?
 
Follow #Globalbio for insights into Japan’s biotech journey and the future of regenerative medicine!
#RegenerativeMedicine #BioJapan #InnovationStrategy #BiotechTransformation